ANAB (AnaptysBio) Tariff Resilience Score: 7/10 (As of Jul. 03, 2026)


ANAB AnaptysBio Inc ANAB
66 GF Score
Price $63.42
GF Value $61.14
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AnaptysBio Tariff Resilience Score?

AnaptysBio ANAB -3.07% 66 Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus rates ANAB with a GF Score™ of 66/100 and a GF Value™ of $61.14 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,373 Biotechnology companies, AnaptysBio ranks better than 90.39% on this metric.

AnaptysBio has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

AnaptysBio has AnaptysBio's focus on biotech R&D limits direct exposure to tariffs. Its supply chain is less affected by international trade, and the industry often benefits from exemptions. However, any changes in raw material tariffs could pose risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AnaptysBio might have Highly Resilient.

AnaptysBio  (NAS:ANAB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AnaptysBio Tariff Resilience Score Related Terms

ANAB vs ABSI, TSHA, RXRX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, AnaptysBio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AnaptysBio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Tariff Resilience Score falls into.


ANAB
66GF Score
AnaptysBio Inc ANAB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
AnaptysBio (ANAB) has a Tariff Resilience Score of 7 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AnaptysBio ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is AnaptysBio's Tariff Resilience Score too high?
AnaptysBio's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. AnaptysBio's value of 7 is 75% above this industry median. Based on the distribution chart, AnaptysBio ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AnaptysBio has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Tariff Resilience Score compare to ABSI and TSHA?
According to the Biotechnology industry distribution chart, AnaptysBio ranks #132 out of 1373 companies for Tariff Resilience Score. This places AnaptysBio in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. AnaptysBio's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AnaptysBio's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnaptysBio's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $61.14, compared to a current price of $63.42 — trading 3.7% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. AnaptysBio's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AnaptysBio (ANAB), the current Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of $63.42 is trading 3.7% above its estimated GF Value™ of $61.14. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • Tariff Resilience Score: 7
  • GF Value™: $61.14 vs. price of $63.42 (3.7% above fair value)
  • GF Score™: 66/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1373)

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
66GF Score

Get the complete analysis for ANAB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$63.42
Price
$61.14
GF Value